Subgroup analyses were further conducted according to clinical and molecular parameters, including sex, chromatin modifier alterations, age, weight, tumor grade, MYC/MYCN alterations, SWI/SNF complex alterations, and activity status of mTOR, Hippo, and receptor tyrosine kinase (RTK) signaling pathways (Figure 2B–L), although inter-subgroup differences were not always statistically significant. The gene discussed is MYCN; the disease is neoplasm.